SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

6-Aminocaproic Acid

Item No. 23724

CAS Registry No.: 60-32-2
Formal Name: 6-amino-hexanoic acid
Synonyms: ε-Aminocaproic Acid, EACA, NSC 26154, NSC 212532, NSC 400230
MF: $C_6H_{13}NO_2$
FW: 131.2
Purity: ≥95%
UV/Vis.: λ_{max}: 202 nm
Supplied as: A crystalline solid
Storage: 4°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

6-Aminocaproic acid is supplied as a crystalline solid. Aqueous solutions of 6-aminocaproic acid can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of 6-aminocaproic acid in PBS, pH 7.2, is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

6-Aminocaproic acid is an inhibitor of the plasmin activating enzymes streptokinase, fibrinokinase, and urokinase (IC_{50}s = ~8 µM for all in an enzyme assay).[1] It is selective for plasmin activating enzymes over trypsin (IC_{50} = >500 µM). 6-Aminocaproic acid inhibits *in vitro* plasmin activation and fibrinolysis in a dose-dependent manner. *Ex vivo*, 6-aminocaproic acid reduces fibrinolysis in dog plasma following i.p. administration at doses ranging from 20-100 mg/kg.[2] Formulations containing 6-aminocaproic acid have been used to decrease postoperative blood transfusion rates following knee surgery.[3]

References

1. Alkjaersig, N., Fletcher, A.P., and Sherry, S. ε-Aminocaproic acid: An inhibitor of plasminogen activation. *J. Biol. Chem.* **234(4)**, 832-837 (1959).
2. Brown, J.C., Brainard, B.M., Fletcher, D.J., *et al*. Effect of aminocaproic acid on clot strength and clot lysis of canine blood determined by use of an in vitro model of hyperfibrinolysis. *Am. J. Vet. Res.* **77(11)**, 1258-1265 (2016).
3. Churchill, J.L., Puca, K.E., Meyer, E., *et al*. Comparing ε-aminocaproic acid and tranexamic acid in reducing postoperative transfusions in total knee arthroplasty. *J. Knee Surg.* **30(5)**, 460-466 (2017).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/03/2023

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM